


# Searching for a true impact of combined therapies of rectal carcinomas in population cancer registry



J. Žaloudík, L. Dušek, J. Mužík

Masaryk Memorial Cancer Institute  
Institute of Biostatistics and Analyses,  
Brno, Czech Republic

- Multidisciplinary assessment and combined therapeutic approach is necessary for more advanced rectal carcinomas - 75% of all
- Various combinations are to be based on personalized approach
- Comparative clinical evaluations of various treatment schedules are available from controlled clinical trials, which may or may not be confirmed in practice
- Data from population cancer registries are
  - a) either - not available
  - b) or - considered to be less „scientific“ than those from trials


... but reflect reality of oncology and address also equity issues

„Big science“ should not diverge too much from reality




# Significant improvement in survival of rectal cancer patients

from 1996-2000 and 2006-2010 by clinical stage




# **Impact of resection margins (R) and postoperative radiotherapy in R1 and R2 rectal carcinoma**

( n = 8301 )



# **Resection margins and total mesorectal excision**


**radial**




**distal**




# Almost none impact of histological grade on overall survival in rectal carcinoma ( n = 9821)



# Impact of chemotherapy in stage III and IV rectal cancer




# Impact of radiotherapy in stage I+II and III rectal cancer



# For improved predictivity we certainly need biobanking

BBMRI.CZ/EU



Are we really facing the era of „personalized“ therapy ?  
... or is it only **better subgrouping or stratification** ?

- 1) **Stage** adjusted therapy ! - OP/RT/CHT-BT
- 2) **Site** adjusted therapy - timing, TME, stoma etc.
- 3) **Resection margins** adjusted therapy ? - postopRT

- 
- 4) **Histological grade** adjusted therapy ?
- 

- 5) **Microvascular invasion** adjusted therapy ?
- 6) **Biomarker/receptor** adjusted therapy – EGFR/Kras only
- 7) **Immune reaction** adjusted therapy ?

*... detailed biomarkers and chemotherapy regimens are not recorded in the Czech National Cancer Registry (functional since 1977)*